Microbial Dynamics in COVID-19: Unraveling the Impact of Human Microbiome on Disease Susceptibility and Therapeutic Strategies.

Microbial Dynamics in COVID-19: Unraveling the Impact of Human Microbiome on Disease Susceptibility and Therapeutic Strategies.

Publication date: Dec 25, 2024

This review explores the bidirectional relationship between the human microbiome and SARS-CoV-2 infection, elucidating its implications for COVID-19 susceptibility, severity, and therapeutic strategies. Metagenomic analyses reveal notable alterations in microbiome composition associated with SARS-CoV-2 infection, impacting disease severity and clinical outcomes. Dysbiosis within the respiratory, gastrointestinal, oral, and skin microbiomes exacerbates COVID-19 pathology through immune dysregulation and inflammatory pathways. Understanding these microbial shifts is pivotal for devising targeted therapeutic interventions. Notably, co-infection of oral pathogens with SARS-CoV-2 worsens lung pathology, while gut microbiome dysbiosis influences viral susceptibility and severity. Potential therapeutic approaches targeting the microbiome include probiotics, antimicrobial agents, and immunomodulatory strategies. This review underscores the importance of elucidating host-microbiota interactions to advance precision medicine and public health initiatives in combating COVID-19 and other infectious diseases.

Concepts Keywords
Covid COVID-19
Gastrointestinal Disease Susceptibility
Pathology Dysbiosis
Probiotics Gastrointestinal Microbiome
Viral Humans
Microbiota
Probiotics
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
disease IDO susceptibility
pathway REACTOME SARS-CoV-2 Infection
disease MESH Dysbiosis
disease MESH co-infection
disease IDO host
disease MESH infectious diseases
disease MESH Long Covid

Original Article

(Visited 1 times, 1 visits today)